US2020199254A1PendingUtilityA1

Identification of vsig8 as the putative vista receptor (v-r) and use thereof to produce vista/vsig8 agonists and antagonists

61
Assignee: IMMUNEXT INCPriority: Dec 5, 2014Filed: Aug 5, 2019Published: Jun 25, 2020
Est. expiryDec 5, 2034(~8.4 yrs left)· nominal 20-yr term from priority
G01N 33/5759C07K 14/70503A61K 39/0011C07K 16/2827C07K 2317/76C12N 2310/14A61P 31/04C07K 2317/73A61P 37/08C12N 2310/531A61P 29/00C07K 16/2803C07K 2317/75A61K 2039/505A61P 35/00C12N 15/1138C07K 2319/30A61P 37/02C07K 16/42G01N 33/57492
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

Claims

exact text as granted — not AI-modified
1 . A compound which agonizes or antagonizes the interaction of VISTA and V-R (VSIG8). 
     
     
         2 - 51 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.